An active learning approach for rapid characterization of endothelial cells in human tumors.
Times cited: 6
Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.
Investigational new drugs.
Times cited: 40
- A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU international. 2007 Academic Article GET IT
- Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference. The Journal of urology. 2007 Conference Paper GET IT
- Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer. Applied Immunohistochemistry and Molecular Morphology. 2005 Academic Article GET IT
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
Times cited: 167